Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. Although the cause of MS is still uncertain, many findings point toward an ongoing autoimmune response to myelin antigens. Because of its location on the outer surface of the myelin sheath and its pathogenicity in the experimental autoimmune encephalomyelitis model, myelin oligodendrocyte glycoprotein (MOG) is one of the potential disease-causing self antigens in MS. However, the role of MOG in the pathogenesis of MS has remained controversial. In this study we addressed the occurrence of autoantibodies to native MOG and its implication for demyelination and axonal loss in MS. We applied a high-sensitivity bioassay, which allowed detecting autoantibodies that bind to the extracellular part of native MOG. Antibodies, mostly IgG, were found in sera that bound with high affinity to strictly conformational epitopes of the extracellular domain of MOG. IgG but not IgM antibody titers to native MOG were significantly higher in MS patients compared with different control groups with the highest prevalence in primary progressive MS patients. Serum autoantibodies to native MOG induced death of MOGexpressing target cells in vitro. Serum from MS patients with high anti-MOG antibody titers stained white matter myelin in rat brain and enhanced demyelination and axonal damage when transferred to autoimmune encephalomyelitis animals. Overall these findings suggest a pathogenic antibody response to native MOG in a subgroup of MS patients.
M
ultiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by inflammation, demyelination, gliosis, and neurodegeneration (1) . Inflammatory infiltrates composed of macrophages/microglia cells, T cells, and B cells are found in MS lesions (2) . In a significant proportion of patients, demyelination appears to be antibody-mediated and complement-dependent, with loss of oligodendrocytes and axonal damage (3) . Despite intensive studies, the etiology of disease still remains uncertain (4) . It is believed that MS results from an autoimmune response to proteins expressed in oligodendrocytes or the myelin sheath (5) . Myelin oligodendrocyte glycoprotein (MOG) is one candidate target self-antigen. MOG expression is confined to the CNS and sequestered at the outermost surface of the myelin sheath (6, 7) . This allows easy access by antibodies from the extracellular space.
MOG induces experimental autoimmune encephalomyelitis (EAE) in a variety of species (8) (9) (10) (11) (12) . In contrast to other models, MOG protein elicited EAE is characterized by a pathogenic antibody response. Although anti-MOG antibodies cannot induce EAE on their own, they strongly enhance T cell and macrophage-initiated demyelination and may augment disease severity (12, 13) . Several studies suggest that the pathogenicity of antibodies resides in their ability to recognize native MOG protein with proper glycosylation and to fix complement, while the significance of antibodies to linear epitopes is still controversial (14) (15) (16) (17) . The role of a specific immune response to MOG in MS patients is less clear. Previous studies have demonstrated that MOG-specific antibodies and T cells are not only detected in MS patients but also in healthy donors (18) . In a recent study, the occurrence of serum anti-MOG and to lesser extent antimyelin basic protein-specific IgM antibodies seemed to predict the incidence of new relapses in early MS patients (19) . However, in a second study, a predictive role of the IgM antibody was not confirmed (20) .
Anti-MOG antibodies are usually determined by Western blot (WB) with a recombinant fragment (amino acids 1-125) of the MOG protein expressed in E. coli (MOG ). Because these WB are performed under denaturing conditions, they detect primarily antibodies to linear epitopes. The detected antibodies belong to the IgM and IgG isotypes (21) but seem to have low affinity to MOG because they cannot be measured by solution phase assays (22) . A recent study indicated that these anti-MOG antibodies were low in serum but enriched in the CNS parenchyma (23) . This finding is consistent with another report demonstrating the presence of antibodies to linear MOG peptide in lesions of EAE animals and MS patients (24) . Although two studies have demonstrated antibodies to full-length MOG in MS patients (25, 26) , none of the studies has characterized antibodies to conformational epitopes of MOG and has assessed their pathogenic role in MS.
Results
Expression of Human MOG in a Human Glioma Line. To obtain MOG in its native form with all posttranslational modifications that may occur in human glial cells, full-length human MOG cDNA was cloned into a lentiviral expression vector and transduced into the human glioblastoma cell line LN18 (LN18 MOG ). The LN18 cell line was also transduced with an empty lentiviral vector to obtain an appropriate control line (LN18 Ctr ), which was grown under the same conditions and solely differed from LN18
MOG by the expression of MOG. Expression of MOG was analyzed with the monoclonal antibody (mAb) 8-18C5 (27) . MOG was expressed in the LN18 MOG line as monomer and dimer ( Fig. 1a) (28) . Surface expression of MOG was confirmed by immunocytochemistry and Author contributions: D.Z., N.S., W.B., H.-P.H., C.S., and B.H. designed research; D.Z., R.S., S.N., V.G., and C.S. performed research; D.Z., R.S., S.N., W.B., C.S., and B.H. analyzed data; and D.Z. and B.H. wrote the paper.
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flow cytometry ( Fig. 1 b and c) . A highly reproducible surface staining was observed at different concentrations of the mAb demonstrating that the LN18 MOG cell line can be used to quantify antibody responses to native MOG (Fig. 1c) . (Fig. 1d) .
Detection of Human
The MOG specificity of the serum antibodies was investigated by competition assays with the mAb 8-18C5. While an irrelevant IgG1 isotype antibody did not compete with the binding of serum antibody, 8-18C5 mAb decreased serum staining in a dosedependent manner (Fig. 1e) . Recombinant MOG did not compete with the binding of serum antibodies, suggesting that the human antibodies, in contrast to 8-18C5 mAb, recognize a strictly conformational epitope not comprised in the recombinant MOG 1-125 (13) . This assumption was further supported by the lack of serum antibody reactivity with recombinant MOG in WB performed under denaturating conditions or immunocytochemistry on paraformaldehyde fixed LN18 MOG cells (data not shown).
Determining Antibodies to Native MOG in MS Patients. The transduced cell lines were then used to quantify antibody responses in serum. We found an increased antibody reactivity to native MOG in MS patients compared with patients with other inflammatory disease of the CNS (OIND; Fig. 2a ) or healthy agematched control donors (HD) (Fig. 2b) . Further stratification of the isotype by secondary antibodies revealed that MS patients differed from controls with respect to IgG but not IgM antibodies to native MOG (data not shown). The same result was obtained in three additional independent patient-control groups, one of them with blinded samples from a multicenter study comparing different methods to detect anti-MOG antibodies. When patients were stratified for their disease course, all MS patient groups had higher antibody levels in serum compared with controls. The number of patients with antibodies against native MOG was highest in primary progressive MS (PP-MS) patients (Fig. 2b ).
Biological Consequences of Human Antinative MOG Antibodies in
Vitro. LN18
Ctr and LN18 MOG cell were incubated with 1:100 diluted anti-MOG antibody-positive or -negative sera and cell survival determined after 20 h. 8-18C5 mAb mixed with anti-MOG antibody-negative serum was used as positive control. 8 -18C5 mAb strongly decreased the cell number of the LN18 MOG but had no effect on LN18 Ctr cells. While antibodynegative sera had no differential effect on LN18 MOG and LN18
Ctr cells, all antibody-positive sera reduced cell numbers of the LN18
MOG compared with the LN18 Ctr cells (Fig. 3 ). Complement activity in anti-MOG antibody-negative and -positive sera did not differ significantly excluding unspecific complement activation as the cause of cytotoxicity (Fig. 3 ).
Demyelinating Property of Human Antinative MOG Antibodies in EAE.
Rat brain sections were incubated with either anti-MOG antibody-positive or -negative sera. 8-18C5 mAb was used as positive control. 8-18C5 strongly stained myelin sheaths in the white matter of the rat brain. A similar staining was observed with sera that contained high titers of antibodies to native MOG, but not with antibody-negative control sera (Fig. 4) .
To test the demyelinating properties of the human anti-MOG antibody, serum was concentrated to obtain an antibody concentration comparable to the amount of the 8-18C5 mAb necessary to produce demyelination in the EAE model (7 fold concentrated). Active EAE was induced by immunization of Lewis rats with guinea pig MBP peptide 72-85. At onset of EAE, animals were divided in groups with a similar disease score of 1-2. The animals received 7-fold concentrated serum of an antibody-negative or an antibody-positive patient by i.v. injection. In addition, concentrated anti-MOG antibody-positive serum was depleted from IgG and also injected in rats. The 8-18C5 mAb was administered at a high concentration, Ϸ10-fold higher than the expected anti-MOG antibodies in the concentrated human serum.
While administration of the human sera had no impact on the EAE score, demyelination and axonal loss were significantly increased in animals injected with antibody-positive serum (Fig.  5a ). The occurrence of demyelination in rats receiving antibodypositive serum was confirmed by electron microscopy (EM) showing demyelinated axons in the perivascular area (data not shown). Similarly, amyloid precursor protein (APP) staining, which strongly correlated with demyelination, was significantly enhanced in the rats receiving the anti-MOG antibody-positive human serum. The APP staining, which probably relates to the susceptibility of demyelinated axons to neurotoxicity, turned out to be better quantifiable than the LFB/PAS staining and thus a more reliable and distinct marker for the antibody effect. Depletion of IgG from the anti-MOG antibody-positive serum significantly reduced APP staining to the level observed with anti-MOG negative serum (Fig. 5b ). These differences were not due to differences in the extent of inflammation. Because the anti-MOG antibody-negative serum contained more complement activity than the antibody-positive serum, unspecific complement activation can be excluded as the cause of the observed pathogenic effects.
Discussion
Despite accumulating evidence that adaptive immune responses play a critical role in the pathogenesis of MS, it has been challenging to identify pathogenic T, B cells, or antibodies. The pathogenic potency of myelin-specific T cells derived from MS patients was formally demonstrated in TCR transgenic mice, but this required a highly artificial setup and active immunization to reliably induce disease (29) . No pathogenic and pathognomonic human B cell clonotype or antibody have been identified in MS so far, although a number of findings support the existence of pathogenic antibodies in this disease (30, 31) . This is different from other human autoimmune diseases such as myasthenia gravis, where pathogenic antibodies have been identified and characterized (32) .
According to the Rose-Witebsky postulates, three criteria need to be met to define an aberrant immune response as autoimmune (33) . The first level of evidence is the least stringent, and only requires the presence of autoantibodies or associations with other autoimmune diseases. The next level calls for indirect evidence, such as induced or spontaneous autoimmune disease reproduced in an experimental animal. These animal models may allow passive transfer of disease. The most convincing evidence for an autoimmune etiology of a human disorder is achieved when the disease can be transferred from person to person.
These criteria have not been met in MS. While elevated antibody titers have been described for a number of self and foreign antigens in MS patients, none of them has proven biological activity. Among all of the autoantibodies in MS that are under investigation, MOG seems to be a promising target. In our study we applied a new strategy to characterize the human antibody response to native MOG. In contrast to previous studies, we expressed the human protein in a human glia cell line to reflect MOG expressed in the human brain as close as possible (25, 26) . The transduced cell line, which stably expresses high levels of MOG on the surface, and a cell line transduced with an empty vector were used to screen for antibodies. We identified serum antibodies against a strictly conformational epitope of MOG. The IgG, but not the IgM, antibody response to native MOG was significantly higher in MS patients compared with Human antibodies to native MOG induce cell death of MOGexpressing target cells. LN18 MOG (gray bars) and LN18 Ctr (black bars) cells were incubated with anti-MOG antibody-positive and -negative MS sera. 8 -18C5 mAb supplemented by serum from an antibody-negative patient was used as control. The cell numbers were determined after 20 h and normalized with the negative control sample (equals 100%). The experiment was performed in duplicate; mean and standard deviation are shown. The complement activity of all of the sera ranged between 50 and 55 CAE unit, without significant difference between anti-MOG antibody-positive and -negative sera. One representative experiment of three is shown. different control groups. In contrast to a previous report, these antibodies were more prevalent in PP-MS than relapsing remitting (RR) MS (26) . The antibodies seem to be directed against the same epitope that elicits a pathogenic antibody response in EAE. Serum with high anti-MOG antibody titers promoted cell death of MOG expressing target cells in vitro. Furthermore, these human anti-MOG antibodies not only stained MOG expressing target cells but also myelin in rat brain comparable to the staining pattern observed with the mAb 8-18C5. The transfer of the human serum to EAE rats precipitated demyelination and consequently damage to demyelinated axons. Although the serum had to be concentrated to generate these effects, the level of the human anti-MOG antibody after injection in the rats was still considerable lower than in the patient's serum. After a single injection, the antibody reached a maximal concentration of less than 40% compared with the concentration in the serum of patients with high titers (0.5 ml 7-fold concentrated human serum injected into rats with a blood volume of Ϸ10 ml). Given the presence of antibody over months in the patients' serum, it is conceivable that this antibody contributes to demyelination and axonal damage in the inflammatory lesion.
The results are in line with pathogenic concepts originating from animal models. While antibodies to linear and conformational epitopes of MOG are generated by immunization with spinal cord homogenate, only those antibodies that target conformational epitopes seem to be pathogenic. These findings parallel the results in human disease. While antibodies to linear epitopes or recombinant fragments of MOG can be detected in MS patients, these antibodies do not bind the native protein nor do they induce pathogenic changes of MOG positive target cells. Their role as biomarkers has remained controversial (19, 20) . In contrast IgG antibodies to native MOG are elevated in a subgroup of MS patients and are pathogenic for MOG expressing cells resulting in demyelination and axonal damage. While not all criteria of the Rose-Witebsky postulates were met, our study provides additional evidence for the autoimmune pathogenesis of MS, and it demonstrates the importance of investigating antibody responses to native autoantigens in autoimmune diseases. Because anti-MOG antibodies are only elevated in a subgroup of patients, further studies have to address how this autoantibody relates to clinical and pathological parameters and whether antibody responses to other native autoantigens play a role in MS. The occurrence of antibodies with demyelinating properties further supports the pathogenic role of the humoral immune system in MS and calls for the development of B cell directed therapies not only for RR but also PP-MS (34, 35) . 
Materials and Methods

Cloning and Expression of MOG.
A human brain total RNA (BD Biosciences) was used to synthesize cDNA. For expression of human full-length MOG (247 aa) using a lentivirus expression system (Invitrogen), the primers 5Ј-ATTGAGATCTGAGATG-GCAAG-3Ј and 5Ј-GAGATCTCAGAAGGGATTTCG-3Ј were used to add BglII restriction sites at 5Ј and 3Ј ends of the MOG cDNA, respectively. The PCR product was cloned into the plasmid pLenti6/V5 (Invitrogen). pLenti6/V5-MOG and the packaging mix were used to transfect a 293FT cell line by Lipofectamine 2000 (Invitrogen). Virus-containing supernatant was used to transduce the human LN18 glioblastoma cell line (36) . As a control, we transduced the LN18 line with an empty vector pLenti6/V5. This stably transduced cell line was maintained under the same conditions as the LN18 MOG line and used as control throughout the experiments. Western Blot Analysis. LN18 MOG or LN18 Ctr were lysed with RIPA buffer (Sigma). Lysate or recombinant MOG (1-125) was separated by 4-15% SDS/PAGE (Invitrogen). The blots were incubated with 1:100 diluted serum or 0.2 g/ml anti-MOG mAb. An HRP-conjugated goat anti-human Ig or anti-mouse Ig (Serotec) was used as secondary antibody. Antibody binding was detected by ECL system (Amersham Biosciences).
Immunocytochemistry and Image Analysis. The immunocytochemistry of LN18 MOG or LN18
Ctr was performed by using standard protocols. The experiment was performed by using 0.3 g/ml anti-MOG mAb or 100-fold-diluted anti-MOG antibody-positive human serum as primary antibody source and an Alexa 488-conjugated goat anti-human Ig or goat anti-mouse Ig (Invitrogen) as secondary antibody. DAPI (Invitrogen) was used for the nuclear staining. Images were captured and analyzed by an Olympus IX71 microscope system. Serum Staining of Rat Brain Sections. Frozen rat brain tissue was sectioned (12-m slices) on a cryostat at Ϫ20°C (Leica). After acetone fixation and blocking of sections, 0.3 g/ml anti-MOG mAb or 100-fold-diluted sera were used as primary antibody, and Alexa 488-conjugated goat anti-human IgG or goat anti-mouse IgG (Invitrogen) was used as secondary antibody. Images were captured and analyzed as described.
Concentration of Human Serum. Anti-MOG positive and negative sera were concentrated by using Amicon Ultra-15 centrifugal filter devices (Millipore). Twenty-two milliliters of serum was concentrated to a final volume of 3 ml. IgG absorption by protein G Sepharose column (Amersham Biosciences) was performed on 1 ml of the serum. The nonconcentrated, concentrated serum, flow-through, and IgG absorbed concentrated sera were analyzed by flow cytometry for anti-MOG antibody titers.
Animal Experiments. Female Lewis rats (Charles River Laboratories) were obtained and kept according to the local animal guidelines. All animals weighed 180 g at immunization and were 6-8 weeks of age. All procedures were performed according to an animal experimentation protocol that was approved by the institutional animal care and use committee at the Georg August University and the Bezirksregierung Braunschweig, Germany. For EAE induction, animals were immunized s.c. with 100 g of guinea pig MBP72-85 (LPQKSQRSQDENPV, purity Ͼ80%; Jerini) emulgated in incomplete Freund's adjuvant (IFA) sub-stituted with 5 mg/ml inactivated Mycobacterium tuberculosis H37 Ra (both from Difco) (38) . Clinical signs of EAE were rated and were cross-checked by independent observers. Five hundred microliters of human serum or 8-18C5 (100 g per animal diluted in anti-MOG antibody-negative serum) was injected into the retrobulbar venous plexus of the animals at a disease score between 1 and 1.5. Thirty hours after serum injection, animals were anesthetized and perfused transcardially with PBS and 4% PFA.
Histology and Immunohistochemistry. Brains and spinal cords were dissected, cut, and embedded in paraffin. Inflammation, demyelination, and axonal damage were assessed by hematoxylin/ eosin staining, Luxol fast blue staining, and immunohistochemistry for APP, a marker for axonal damage (Clone 2C11; Chemicon). Bound antibody was visualized by using an avidinbiotin technique with 3,3Ј-diaminobenzidine as chromogen. The extent of inflammation is given as the number of inflammatory infiltrates/rat spinal cord cross-section. For the assessment of perivascular demyelination and axonal damage in transferred EAE rats, the number of vessels with perivascular demyelination and axonal damage per spinal cord cross-section was determined. All analyses were performed by a blinded investigator (C.S.). At least 20 stained spinal cord cross-sections per rat were examined.
Statistical Analysis. Kruskal-Wallis nonparametric analysis was performed for the comparison of antibody titer in patients and controls (normality was not passed for t test). A t test was used for comparison of LFB or APP score in rats treated with different sera. The analysis was performed by SigmaStat 3.0 (Systat).
